Lates News

According to AI Express of Every Economy, on August 21, Great Wall Guorui Securities issued a research report giving a buy rating to Huadong Medicine (000963.SZ). The rating reasons include: 1) steady revenue growth, driven by the pharmaceutical industry with outstanding performance; 2) innovative product business revenue exceeding 1 billion yuan, entering a high-growth channel; 3) deep cultivation in three major treatment areas, with breakthroughs in the research and development pipeline of innovative drugs exceeding 80 items; 4) overall sales trend of industrial microorganisms sector continuing to improve; 5) medical beauty business under temporary pressure, showing a trend of improvement on a month-on-month basis. (Daily Economic News)